Payal Kapur, M.D.
Professor
- Endowed Title
- Jan and Bob Pickens Distinguished Professorship in Medical Science, in Memory of Jerry Knight Rymer and Annette Brannon Rymer and Mr. and Mrs. W.L. Pickens
- School
- Medical School
- Department
- Pathology | Urology
You have reached the Academic Profile.
For more information on the doctor and patient care, please visit the clinical profile.
Dr. Kapur completed her medical education in 1997 at the University College of Medical Sciences (UCMS), New Delhi, India. After completing a pathology residency in 2000 at Maulana Azad Medical College, New Delhi, she was awarded the Dr. RP Mathur Memorial Award for the best outgoing III year pathology resident. Subsequently, she came to Dallas and did a Residency in Anatomic and Clinical Pathology at UT Southwestern Medical Center (2002-2006). She is certified in Anatomic Pathology and Clinical Pathology by the American Board of Pathology.
Currently she is on faculty in the Department of Pathology and Urology at UT Southwestern and the Group Leader of Genitourinary Pathology and the Co-Leader of the Kidney Cancer Program at Simmons Cancer Center. She is the Pathology representative at the UT Southwestern weekly Urology Spence Conference, and monthly Multidisciplinary Renal Cell Carcinoma Tumor Board.
She is actively involved in Anatomic Pathology residency education and received the Vernie A. Stembridge, M.D. Resident Teaching Award in 2010 and 2011. Dr. Payal Kapur was the former Assistant Director (Anatomic Pathology) of UT Southwestern Pathology Residency Training (2010-2013), the Co-Director of UT Southwestern Tumor Registry Core Facility at Simmons Cancer Institution (2008-2013), the Director of the Philip O’Brien Montgomery Visiting Lectureship (2007-2013), and the Director of the Anatomical Pathology Resident Education Seminar Series (2007-2013). She was also the former Medical Director of Surgical Pathology at Parkland Hospital (2013-2015)
Dr. Kapur’s research is focused on characterizing adult genitourinary tumors and developing prognostic, therapeutic, and diagnostic biomarkers. She has extensive experience in developing immunohistochemistry (IHC) tests, and of greatest relevance to the field of kidney cancer.